[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31370":3,"doc-seo-31370":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31370,8796095360427,"Lucas Martin","https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d",7,"Healthcare","GRAPPA 2021 Treatment Recommendations for Psoriatic Arthritis","GRAPPA 2021 treatment recommendations for psoriatic arthritis (PsA) were presented during the GRAPPA 2022 annual meeting, emphasizing their international orientation and early inclusion of patient views. The domain-based framework was refined compared with the 2015 version by splitting the comorbidities group into two related sets, enabling inflammatory bowel disease and uveitis to be incorporated into the key treatment algorithm. A GRADE-informed approach graded evidence quality across multiple PsA domains and incorporated comorbidities to anticipate adverse events and influence treatment selection.","cbCait0vD5rkBs6l","https://ap.wps.com/l/cbCait0vD5rkBs6l","pdf",106862,1,2,"English","en","# Abstract and Presentation Overview\n## Domain-Based Approach and Comorbidity Integration\n## Evidence Grading and Scope of Domains","[{\"question\":\"What distinguishes the GRAPPA 2021 PsA treatment recommendations presented at the GRAPPA 2022 annual meeting?\",\"answer\":\"They highlight a truly international approach, the inclusion of patient views from the start, representation by both rheumatologists and dermatologists, and coverage across diverse PsA domains, with comorbidities included to inform adverse events and treatment choices.\"},{\"question\":\"How did the comorbidities section change compared with the 2015 recommendations?\",\"answer\":\"The comorbidities were split into two different groups addressing related conditions, which allowed additional PsA-related conditions—specifically inflammatory bowel disease and uveitis—to be added into the key treatment algorithm.\"},{\"question\":\"How were the recommendations developed and graded?\",\"answer\":\"A GRADE-informed methodology was used to provide a transparent approach to grading the quality of evidence supporting the recommendations.\"}]",1779397252,5,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":83,"head_meta":85,"extra_data":87,"updated_unix":25},105,"grappa-2021-treatment-recommendations-for-psoriatic-arthritis","",{"@graph":34,"@context":82},[35,51,65],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,45,48],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":20},"https://docshare.wps.com/document/","Document",{"item":46,"name":12,"@type":41,"position":47},"https://docshare.wps.com/document/healthcare/",3,{"item":49,"name":13,"@type":41,"position":50},"https://docshare.wps.com/document/grappa-2021-treatment-recommendations-for-psoriatic-arthritis/31370/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":59,"encodingFormat":58,"isAccessibleForFree":60,"interactionStatistic":61},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":39,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-05-21",true,{"@type":62,"interactionType":63,"userInteractionCount":4},"InteractionCounter",{"@type":64},"ViewAction",{"@type":66,"mainEntity":67},"FAQPage",[68,74,78],{"name":69,"@type":70,"acceptedAnswer":71},"What distinguishes the GRAPPA 2021 PsA treatment recommendations presented at the GRAPPA 2022 annual meeting?","Question",{"text":72,"@type":73},"They highlight a truly international approach, the inclusion of patient views from the start, representation by both rheumatologists and dermatologists, and coverage across diverse PsA domains, with comorbidities included to inform adverse events and treatment choices.","Answer",{"name":75,"@type":70,"acceptedAnswer":76},"How did the comorbidities section change compared with the 2015 recommendations?",{"text":77,"@type":73},"The comorbidities were split into two different groups addressing related conditions, which allowed additional PsA-related conditions—specifically inflammatory bowel disease and uveitis—to be added into the key treatment algorithm.",{"name":79,"@type":70,"acceptedAnswer":80},"How were the recommendations developed and graded?",{"text":81,"@type":73},"A GRADE-informed methodology was used to provide a transparent approach to grading the quality of evidence supporting the recommendations.","https://schema.org",{"og:url":49,"og:type":84,"og:title":13,"og:site_name":56,"og:description":14},"article",{"robots":86,"canonical":49},"index,follow",{"doc_id":7,"site_id":30}]